Published in Cancer Discov on July 11, 2014
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. Cancer Sci (2017) 0.75
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget (2017) 0.75
Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression. Oncogene (2017) 0.75
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc (2012) 35.75
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics (2009) 6.08
A mutator phenotype in cancer. Cancer Res (2001) 4.41
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Identification and characterization of three members of the human SR family of pre-mRNA splicing factors. EMBO J (1995) 3.56
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature (1984) 3.15
Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet (2007) 3.12
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (2007) 3.06
Cancer genome sequencing: a review. Hum Mol Genet (2009) 2.15
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther (2012) 2.05
Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods (2009) 1.98
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem (2006) 1.80
Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer (2005) 1.70
The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence. Genes Chromosomes Cancer (2005) 1.70
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov (2013) 1.69
Toll-like receptors are key participants in innate immune responses. Biol Res (2007) 1.45
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene (2009) 1.40
Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov (2013) 1.39
Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J Clin Endocrinol Metab (2001) 1.29
Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res (2010) 1.25
Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res (2009) 1.18
Induction of transformation and DNA synthesis after microinjection of raf proteins. Mol Cell Biol (1990) 1.08
Targeting LKB1 signaling in cancer. Biochim Biophys Acta (2012) 1.07
Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett (2004) 1.01
GAPex-5 mediates ubiquitination, trafficking, and degradation of epidermal growth factor receptor. J Biol Chem (2007) 1.00
Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res (2003) 0.99
90-kDa ribosomal S6 kinase is a direct target for the nuclear fibroblast growth factor receptor 1 (FGFR1): role in FGFR1 signaling. J Biol Chem (2004) 0.99
The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J Biol Chem (2007) 0.96
Biology and significance of signalling pathways activated by IGF-II. Growth Factors (2011) 0.88
Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase. Oncogene (1995) 0.85
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Eur J Cancer (2009) 0.85
Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol Cancer Res (2007) 0.82
Molecular cloning and characterization of a protein tyrosine phosphatase enriched in testis, a putative murine homologue of human PTPMEG. Gene (2000) 0.79
Semaphorins in lung cancer. J Thorac Oncol (2006) 0.77